| Literature DB >> 30828264 |
Nanmu Yang1,2,3, Jinxue Zhou2,3, Qingjun Li2,3, Feng Han2,3, Zujiang Yu1.
Abstract
BACKGROUND: The aim of this research was to investigate the mechanism of miR-96 affecting hepatocellular carcinoma (HCC).Entities:
Keywords: AKT/GSK-3β/β-catenin; FOXO1; HepG2 cells; Proliferation; miR-96
Year: 2019 PMID: 30828264 PMCID: PMC6381685 DOI: 10.1186/s12935-019-0756-7
Source DB: PubMed Journal: Cancer Cell Int ISSN: 1475-2867 Impact factor: 5.722
Fig. 1Up-regulation of miR-96 and down-regulation of FOXO1 in tumor tissues and HepG2 cells. a miR-96 relative expression in tumor tissues and non-tumor tissues by qRT-PCR; b FOXO1 mRNA relative expression in tumor tissues and non-tumor tissues by qRT-PCR; c FOXO1 protein relative expression in tumor tissues and non-tumor tissues by Western blot; d miR-96 relative expression in L02 and HepG2 cells by qRT-PCR; e FOXO1 mRNA relative expression in L02 and HepG2 cells by qRT-PCR; f FOXO1 protein relative expression in L02 and HepG2 cells by Western blot. **P < 0.01
The relationship between clinical features and expression levels of miR-96 and FOXO1
| Clinical features | n | Relative of miR-96 expression | Relative of FOXO1 expression | ||||
|---|---|---|---|---|---|---|---|
| Lymph node metastasis | 2.61 | 0.02 | − 2.14 | 0.04 | |||
| Positive | 11 | 2.45 ± 0.29 | 0.31 ± 0.13 | ||||
| Negative | 16 | 2.24 ± 0.12 | 0.44 ± 0.17 | ||||
| Infiltration | 2.34 | 0.03 | − 2.55 | 0.02 | |||
| Positive | 13 | 2.53 ± 0.26 | 0.38 ± 0.11 | ||||
| Negative | 14 | 2.33 ± 0.18 | 0.51 ± 0.15 | ||||
| Differentiation | 2.15 | 0.04 | − 2.16 | 0.04 | |||
| Low-medium | 19 | 2.38 ± 0.22 | 0.35 ± 0.12 | ||||
| High | 8 | 2.19 ± 0.18 | 0.48 ± 0.19 |
Fig. 2FOXO1 was directly suppressed by miR-96. a Prediction of binding sites for FOXO1 and miR-96 by Target Scan; b Luciferase reporter assay; c FOXO1 mRNA expression by qRT-PCR; d FOXO1 protein expression by Western blot. ##P < 0.01 when compared with WT + NC group; **P < 0.01 when compared with Blank group or miR-NC group
Fig. 3FOXO1 inhibited proliferation, migration and invasion of HepG2 cells induced by miR-96 in vitro. a Detection of cells proliferation by MTT assay. *P < 0.05 when compared with NC + Vector group, #P < 0.05 when compared with mimics + Vector group; b Detection of cells migration by Transwell. **P < 0.01; c Detection of cells invasion by Transwell. **P < 0.01
Fig. 4FOXO1 inhibited tumor growth induced by miR-96 in nude mice. a Tumor volume after subcutaneous transplantation for 5 weeks; b FOXO1-positive cells of xenograft tumors by immunohistochemical analysis. Arrow indicated FOXO1-positive cells. **P < 0.01
Fig. 5miR-96 activated AKT/GSK-3β/β-catenin signaling pathway through targeted inhibition of FOXO1. Detection of AKT and p-AKT protein (a), GSK-3 and p-GSK-3 protein (b), and β-catenin and p-β-catenin protein (c) by Western blot (d) by western blot in vivo. **P < 0.01
Fig. 6FOXO1 inhibited β-catenin entry into the nucleus induced by miR-96. Expression of β-catenin in nucleus (a) and cytoplasm (b) was detected by Western blot. c Distribution of β-catenin in nucleus and cytoplasm was monitored by immunofluorescence